Clinical characteristics | NC (n = 25) | SLE LN− (n = 15) | SLE LN+ (n = 15) | p valued | ||
---|---|---|---|---|---|---|
SLE LN− vs. NC | SLE LN+ vs. NC | SLE LN+ vs. SLE LN− | ||||
Age (mean + SD) | 32.2 ± 9.04 | 28.2 ± 6.7 | 30.13 ± 7.68 | n.s. | n.s. | n.s. |
Sex (M/F) | 5/20 | 2/13 | 2/13 | n.s. | n.s. | n.s. |
Disease duration (months) | - | 4.90 ± 4.18 | 3.33 ± 4.21 | - | - | n.s. |
SLEDAI | - | 9.06 ± 4.06 | 14.93 ± 4.65 | - | - | 0.001 |
1997 ACR classification criteria for SLE | ||||||
 Malar rash | - | 8 | 11 | - | - | - |
 Discoid rash | - | 1 | 3 | - | - | - |
 Photosensitivity | - | 4 | 3 | - | - | - |
 Oral ulcers | - | 2 | 1 | - | - | - |
 Nonerosive arthritis | - | 8 | 6 | - | - | - |
 Pleuritis or pericarditis | - | 1 | 3 | - | - | - |
 Renal disorder | - | 0 | 15 | - | - | - |
 Neurological disorder | - | 1 | 0 | - | - | - |
 Hematological disorder | - | 2 | 7 | - | - | - |
 Immunological disorder | - | 11 | 12 | - | - | - |
 Positive antinuclear antibody (ANA) | - | 15 | 14 | - | - | - |
WBC (×109/L)a | - | 6.64 ± 0.70 | 6.45 ± 0.90 | - |  | 0.866 |
Neutrophils (×109/L)b | - | 5.00 ± 0.69 | 4.74 ± 0.76 | - |  | 0.799 |
Lymphocytes (×109/L)c | - | 1.54 ± 0.21 | 1.22 ± 0.18 | - |  | 0.246 |
C3 (mg/dL) | - | 534.5 ± 280.1 | 293.2 ± 196.2 | - |  | 0.0108 |
C4 (mg/dL) | - | 133.2 ± 147.4 | 88.02 ± 86.48 | - |  | 0.3145 |